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Bone morphogenetic proteins 9 and 10 (BMP9/BMP10) are
circulating cytokines with important roles in endothelial
homeostasis. The aim of this study was to investigate the roles
of BMP9 and BMP10 in mediating monocyte–endothelial
interactions using an in vitro flow adhesion assay. Herein,
we report that whereas BMP9/BMP10 alone had no effect
on monocyte recruitment, at higher concentrations both
cytokines synergized with tumor necrosis factor- (TNF)
to increase recruitment to the vascular endothelium. The
BMP9/BMP10-mediated increase in monocyte recruitment
in the presence of TNF was associated with up-regulated
expression levels of E-selectin, vascular cell adhesion mole-
cule (VCAM-1), and intercellular adhesion molecule 1
(ICAM-1) on endothelial cells. Using siRNAs to type I and II
BMP receptors and the signaling intermediaries (Smads), we
demonstrated a key role for ALK2 in the BMP9/BMP10-in-
duced surface expression of E-selectin, and both ALK1 and
ALK2 in the up-regulation of VCAM-1 and ICAM-1. The type
II receptors, BMPR-II and ACTR-IIA were both required for
this response, as was Smad1/5. The up-regulation of cell sur-
face adhesion molecules by BMP9/10 in the presence of
TNFwas inhibited by LDN193189, which inhibits ALK2 but
not ALK1. Furthermore, LDN193189 inhibited monocyte
recruitment induced by TNF and BMP9/10. BMP9/10
increased basal IB protein expression, but did not alter
p65/RelA levels. Our findings suggest that higher concentra-
tions of BMP9/BMP10 synergize with TNF to induce the
up-regulation of endothelial selectins and adhesion mole-
cules, ultimately resulting in increased monocyte recruit-
ment to the vascular endothelium. This process is mediated
mainly via the ALK2 type I receptor, BMPR-II/ACTR-IIA
type II receptors, and downstream Smad1/5 signaling.
The vascular endothelium is a key regulator of vascular
homeostasis with important roles in regulating blood pressure,
coagulation, leukocyte trafficking, and angiogenesis (1–3). The
normal vascular endothelium regulates the passage of circulat-
ing cells into the interstitial space through several mechanisms,
including leukocyte recruitment and alterations in permeabil-
ity. However, endothelial dysfunction initiates a series of events
triggering aberrant endothelial activation that can lead to
chronic pathological permeability and leukocyte adherence
(4), which contribute to cardiovascular diseases, including
atherosclerosis.
Chronic systemic inflammation is associated with many car-
diovascular, rheumatological, and respiratory diseases (5–7),
principally through the pathological activation of the vascular
endothelium. Inflammatory cytokines including tumor necro-
sis factor  (TNF) and interleukin-1 are elevated in athero-
sclerosis. This promotes the up-regulation of endothelial-ex-
pressed cell surface proteins that mediate leukocyte adhesion,
including P- and E-selectin, which are involved in the initial
leukocyte capture, and intercellular adhesion molecule 1
(ICAM-1),4 and vascular cell adhesion molecule 1 (VCAM-1),
which regulate the firm adhesion and transmigration of leuko-
cytes (8–10).
Bone morphogenetic proteins (BMPs) are ligands belonging
to the TGF superfamily. Aberrant BMP2, BMP4, and BMP6
signaling have been associated with the inflammation, fibrosis,
calcification, and osteogenesis that are associated with the
pathophysiology of atherosclerosis (11–17). Because BMP9 and
BMP10 are potent mediators of endothelial function it is likely
that they also contribute to the pathobiology of vascular dis-
eases such as atherosclerosis. However, the role played by
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BMP9 and BMP10 in monocyte transmigration across the
endothelium, one of the initiating steps in atherosclerosis, has
not been studied. BMP9 is a key regulator of vascular quies-
cence (18, 19), and has been shown to protect the endothelium
through the inhibition of vascular permeability (20), endothe-
lial proliferation (18), angiogenesis (21), and lymphangiogen-
esis (22, 23). Although BMP9 has been more extensively char-
acterized than BMP10, in cell culture experiments BMP10
regulates a similar set of genes as BMP9 (24) and BMP10 can
substitute for BMP9 in a mouse model of postnatal retinal vas-
cular remodeling (21). Moreover, similar to BMP9, BMP10 has
been described as a mediator of flow-dependent arterial quies-
cence (25). These studies suggest an overlapping role and func-
tion for BMP9 and BMP10 in the vasculature.
BMP serine-threonine kinase receptors form heterodimeric
complexes consisting of type I and type II receptors (26). BMP9
and BMP10 signal through type I and type II receptors
expressed on endothelial cells, including the type I recep-
tors, activin-like kinase (ALK) 1 and ALK2, and the type II
receptors, bone morphogenetic protein receptor 2 (BMPR-II
encoded by BMPR2), activin receptor 2A (ACTR-IIA encoded
by ACVR2A), and activin receptor 2B (ACTR-IIB encoded by
ACVR2B) (24, 27, 28). Optimal BMP9 and BMP10 signaling
requires the type III auxiliary receptor endoglin, also expressed
on endothelial cells (27). Mutations in BMP9 and its’ receptors
underlie vascular diseases, namely hereditary hemorrhagic tel-
angiectasia (ALK1, endoglin, and BMP9) (29–31) and pulmo-
nary arterial hypertension (ALK1, BMPR2) (32–34). Further-
more, endothelial deletion of Bmpr2 in mice enhances the
development of atherosclerosis, suggesting an atheroprotective
protective role for BMPR-II (35).
Activated BMP receptors transduce their signal primarily
through phosphorylation of Smad1, Smad5, and Smad8. Fol-
lowing activation, Smads formheteromeric complexes with the
common partner Smad, Smad4 (26). These complexes translo-
cate to the nucleus and regulate the expression of numerous
genes through binding to promoter regions, usually in complex
with other transcription factors. The best characterized targets
of BMP/Smad signaling are the inhibitor of differentiation (ID)
genes, which possess Smad-binding elements in their promot-
ers (36).
BMP9 signaling has been implicated previously in neutrophil
recruitment to the endothelium, both directly (37) and
indirectly (38–40). BMP9 has previously been shown to up-
regulate E-selectin and VCAM-1 on LPS-stimulated blood out-
growth endothelial cells (37) and endothelial cell surface-ex-
pressed endoglin enhances leukocyte recruitment through the
activation of 1-integrins expressed on the surface of leuko-
cytes (40). Furthermore, BMPR2-deficient endothelium shows
impaired leukocyte recruitment (38, 39), thus further implicat-
ing BMP9 signaling in the process of leukocyte recruitment.
Monocyte recruitment to the vascular endothelium is a key
mediator of the progression of atherosclerotic lesions (41,
42). Although there is a growing body of evidence associating
BMP9 signaling with neutrophil recruitment, the role of
BMP9 and BMP10 in monocyte recruitment to the vascular
endothelium has yet to be reported. In the current study we
show, using an in vitro flow adhesion assay that both BMP9
and BMP10, in a concentration-dependent manner, syner-
gistically enhance monocyte recruitment to TNF-stimu-
lated human aortic endothelial cells (HAECs). This occurs
through the up-regulation of E-selectin, VCAM-1, and
ICAM-1 onHAECs, andmainly via the type I receptor ALK2,
the type II receptors BMPR-II/ACTR-IIA, and the down-
stream mediators Smad1/5.
Results
BMP9 and BMP10 increasemonocyte recruitment to TNF-
treated HAECs in a concentration-dependentmanner
First, we investigated the role of BMP9 andBMP10 onmono-
cyte recruitment to the vascular endothelium using an in vitro
flow adhesion assay, which enables the quantification of real-
time interactions between endothelial cells and leukocytes
under conditions of physiological flow. As BMP9 has been
reported to circulate at concentrations between 2 and 12 ng/ml
in humans (18, 43), we exposed the endothelium to BMP9 or
BMP10 at concentrations ranging from0 to 5 ng/ml prior to the
addition of TNF, then assessed monocyte recruitment. Negli-
gible monocyte recruitment was observed in HAECs treated
with BMP9 (Fig. 1, A and B) or BMP10 (Fig. 1, A and C) alone.
Although TNF treatment, as previously reported (2, 44, 45),
induced some monocyte recruitment to HAEC monolayers
(Fig. 1, A–C), a synergistic increase in total monocyte recruit-
ment was observed when TNF-stimulated HAECs were pre-
treated with BMP9 or BMP10 at concentrations equal to or
higher than 1.5 ng/ml (Fig. 1, A–C). Pre-treatment of the vas-
cular endothelium with BMP9 or BMP10 did not affect the
percentage of rolling, arrested, or transmigrated monocytes
(Fig. 1, D and E). Only minimal monocyte rolling was observed
in these experiments, suggesting that this process is rapidly
followed by arrest and transmigration. Maximal monocyte
recruitment was observed when TNF-stimulated HAECs
were pre-treated with BMP9 or BMP10 at a concentration of 5
ng/ml, consequently, this concentration was used in all subse-
quent experiments. To examine whether this response was
restricted to aortic cells, we also assessed the influence of BMP9
and BMP10 on TNF-dependent recruitment of monocytes to
blood outgrowth endothelial cell (BOEC) monolayers (46).
Similar to HAECs, BMP9 and BMP10 did not influence mono-
cyte adhesion to BOECs, but enhanced the recruitment
observed in response to TNF (Fig. 1, F andG). Taken together,
these data show that both BMP9 and BMP10 synergize with
TNF to enhance monocyte recruitment to the vascular endo-
thelium in a concentration-dependent manner, at or above 1.5
ng/ml.
BMP9 and BMP10 increase expression of adhesionmolecules
and BMP2 in TNF-treated HAECs
Next, we used quantitative PCR (qPCR) and flow cytometry
to identify whether pre-treatment with BMP9 or BMP10
increased expression of the endothelial selectins and adhesion
molecules involved in monocyte recruitment in TNF-stimu-
lated HAECs. In accordance with previous studies (47–50),
TNF induced gene and surface protein expression of E-selec-
tin, VCAM-1, and ICAM-1, which were synergistically
increased in HAECs (Fig. 2, A–F, and supplemental Fig. S1) or
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BOECs (supplemental Fig. S2, A–C) pre-treated with either
BMP9 or BMP10 (5 ng/ml). BMP9 and BMP10 alone had no
effect on the expression of these adhesionmolecules. P-selectin
was not detected on HAECs with any of the treatments (data
not shown).
Because BMP2, BMP4, and BMP6 have been previously
implicated in inflammation, fibrosis, and osteogenesis (11–13),
we next investigated whether treatment with BMP9 or BMP10
increased expression of these ligands in HAECs. BMP9 and
BMP10 alone induced the expression of BMP2 by 3–4-fold in
HAECs, whereas TNF exerted a weak induction (Fig. 2G).
However, pre-treatment with either BMP9 or BMP10 prior to
TNF stimulation accentuated BMP2 expression in HAECs
(Fig. 2G). BMP4 was slightly repressed by BMP9, BMP10, and
TNF, whereas BMP6 expression did not change with any of
the conditions tested (Fig. 2, H and I). Taken together, these
Figure 1. BMP9 and BMP10 increase monocyte recruitment to TNF-stimulated HAECs in a concentration-dependent manner. HAECs were treated with
BMP9 and BMP10 16 h prior to TNF treatment (0.05 ng/ml, 4 h). Monocyteswere perfused over TNF-stimulatedHAECs in a flow adhesion assay in the presence of
media alone, BMP9 or BMP10. A, representative images of HAECmonolayers that were untreated, or treated with BMP9 (5 ng/ml), BMP10 (5 ng/ml), TNF, BMP9
TNF, or BMP10 TNF. Adherent monocytes are the bright phase cells (white arrow) and transmigrated monocytes shown as the smaller dark phase cells (black
arrow). Experiments were performed in triplicate and the data are representative of n  3 biological repeats. B and C, concentration-response analysis of the
recruitment of monocytes to HAEC monolayers, in the presence or absence of TNF, with increasing concentrations of BMP9 (B) (0–5 ng/ml) and BMP10 (C) (0–5
ng/ml). D and E, monocyte behavior (rolling, clear bar; adherence, gray bar; and transmigration, black bar) was expressed as a percentage of total recruitment to
TNF-stimulatedHAECs in thepresenceofBMP9 (D) andBMP10 (E). F,analysis of the recruitmentofmonocytes toBOECmonolayers, treatedwith5ng/mlof BMP9or
BMP10, inthepresenceorabsenceofTNF.G,monocytebehavior (rolling,clearbar; adherence,graybar; andtransmigration,blackbar)wasexpressedasapercentage
of total recruitment to TNF-stimulated BOECs in the presence of BMP9 or BMP10. Error bars represent S.E. *, p 0.05; **, p 0.01; ***, p 0.001.
Figure 2. BMP9 and BMP10 increase the expression of E-selectin, VCAM-1, ICAM-1, and BMP2 in TNF-stimulated HAECs. HAECS were treated with
BMP9 or BMP10 (5 ng/ml, 16 h) prior to TNF treatment (0.05 ng/ml, 4 h). Expression of SELE (E-selectin) (A), VCAM1 (B), and ICAM1 (C) mRNA assessed using
qPCR. Surface expression of E-selectin (FITC-conjugated anti-human E-selectin) (D), VCAM-1 (PE-Cy5-conjugated anti-human VCAM-1) (E), and ICAM-1 (APC-
conjugated anti-human ICAM-1) (F) was assessed using flow cytometry. Data are shown as median fluorescence intensity (MFI) expressed as fold-change
relative to untreatedHAECs. Expression of BMP2 (G), BMP4 (H), and BMP6 (I) mRNA assessed using qPCR. Experimentswere performed in triplicate and the data
are representative of n 3 biological repeats. Error bars represent mean S.E. *, p 0.05; **, p 0.01; ***, p 0.001.
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data reveal that both BMP9 and BMP10 synergize with TNF
to up-regulate endothelial-expressed molecules involved in
leukocyte recruitment, in addition to BMP2, a factor previously
implicated in endothelial inflammation.
BMP6 increases the surface expression of adhesionmolecules
on TNF-treated HAECs
BMP6 has been previously described as a factor that induces
endothelial inflammation (11). BMP6 transduces signaling pre-
dominantly via the type I receptor ALK2, and not ALK1 (11,
51). Therefore, we investigated the potential role of BMP6/
ALK2 in inducing E-selectin, VCAM-1, and ICAM-1 surface
expression in HAECs. BMP6 pre-treatment induced a marked
up-regulation of the surface expression levels of E-selectin,
VCAM-1, and ICAM-1 in TNF-treated HAECs (Fig. 3, A–C).
The up-regulation in E-selectin and VCAM-1 in response to
BMP6 was completely abrogated by the use of a neutralizing
anti-BMP6 antibody (Fig. 3, A and B). Treatment with the
BMP6-targeted antibody did not cause any further reduction in
ICAM-1 (Fig. 3C), indicating that ICAM-1 surface protein
expression is regulated through a different mechanism to E-se-
lectin and VCAM-1.
We next determined whether the BMP9/BMP10-induced
up-regulation of adhesion molecules was mediated by
BMP6. Treatment with the anti-BMP6 neutralizing antibody
likewise had no effect on the surface expression levels of
adhesion molecules induced by BMP9, BMP10, and TNF
treatments, indicating that this process was not mediated by
BMP9 or BMP10 (Fig. 3,D–H). Collectively, these data imply
a dominant role for ALK2-mediated effects of BMPs in the
up-regulation of surface expression levels of endothelial
adhesion molecules.
Figure3.BMP6 increasestheexpressionofE-selectin,VCAM-1,andICAM-1inTNF-stimulatedHAECs.HAECSweretreatedwithaBMP6neutralizingantibody
(BMP6 ab) 60 min prior to the addition of BMP6 (25 ng/ml, 16 h) followed by TNF (0.05 ng/ml; 4 h). Surface expression of E-selectin (FITC-conjugated anti-human
E-selectin) (A), VCAM-1 (PE-Cy5-conjugatedanti-humanVCAM-1) (B), and ICAM-1 (APC-conjugatedanti-human ICAM-1) (C)wasassessedusing flowcytometry.HAECs
were treatedwith aBMP6neutralizingantibody (BMP6ab) 60minprior to theadditionof BMP9 (5ng/ml, 16h) followedbyTNF (0.05ng/ml, 4h). Surface expression
ofE-selectin (FITC-conjugatedanti-humanE-selectin) (D), VCAM-1 (PE-Cy5-conjugatedanti-humanVCAM-1) (E), and ICAM-1 (APC-conjugatedanti-human ICAM-1) (F)
was assessed using flow cytometry. HAECswere treatedwith a BMP6neutralizing antibody (BMP6 ab) 60min prior to the addition of BMP10 (5 ng/ml, 16 h) followed
by TNF (0.05 ng/ml, 4 h). Surface expression of E-selectin (FITC-conjugated anti-human E-selectin)(G), VCAM-1 (PE-Cy5-conjugated anti-human VCAM-1)(H), and
ICAM-1(APC-conjugatedanti-humanICAM-1) (I)wasassessedusingflowcytometry.ForwardscatterandsidescattergatingwasappliedtotheHAECpopulation.Data
are shown asmedian fluorescence intensity (MFI) expressed as fold-change relative to untreated HAECs. Experiments were performed in triplicate and the data are
representative of n 3 biological repeats. Error bars representmean S.E. *, p 0.05; **, p 0.01; ***, p 0.001; ns, not significant.
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The role of type I receptors in BMP9- and BMP10-induced
expression of adhesionmolecules
Expression analysis for the BMP type I receptors in HAECs
revealed that BMP9 and BMP10 induced the expression of
ALK1 and ALK2, with little effect on ALK3 (supplemental Fig.
S3, A–C). ALK6 was not expressed. Addition of TNF slightly
reduced the expression of ALK1, but not ALK2. To determine
the BMP type I receptors mediating the BMP9- and BMP10-
induced up-regulation in adhesion molecules in response to
TNF, we performed siRNA knockdown of ALK1 and ALK2
and assessed surface expression of adhesion molecules. The
dependence of each adhesion molecule on ALK1 or ALK2 was
different. The increase in cell surface E-selectin expression
observed in HAECs pre-treated with BMP9 or BMP10 prior
to TNF was inhibited by ALK2 knockdown, but not ALK1
knockdown (Fig. 4A), suggesting a marked ALK2 depen-
dence of E-selectin regulation by BMP9 or BMP10 in these
experiments. Knockdown of ALK1 together with ALK2 did
not impact further on E-selectin expression. For VCAM-1
individual siRNA knockdown of ALK1 and ALK2 substan-
tially impaired BMP9- and BMP10-induced VCAM-1 ex-
pression, and their combined knockdown further inhib-
ited surface VCAM-1 expression (Fig. 4B). For ICAM-1, only
combined ALK1 and ALK2 knockdown resulted in impaired
BMP9- and BMP10-induced surface ICAM-1 expression
(Fig. 4C). The knockdown efficiency of siALK1 and siALK2
in HAECs confirmed85% reduction in mRNA levels of the
corresponding target gene (supplemental Fig. S3, D and E).
We also confirmed that siALK1, but not siALK2, reduced the
ID1 induction by BMP9 and BMP10 in HAECs (supplemen-
tal Fig. S4). These data show that ALK2 is essential for
BMP9- and BMP10-induced E-selectin expression, whereas
either ALK1 or ALK2 can increase VCAM-1 expression.
ICAM-1 requires both ALK1 and ALK2 for up-regulation in
TNF-stimulated HAECs.
To explore further the role of type I receptors in the BMP9/
BMP10-induced expression of adhesion molecules in TNF-
stimulatedHAECs, we employed LDN193189, a cell permeable
small molecule inhibitor of BMP type I receptors. LDN193189
inhibits ALK2with an IC50 of 5 nM, andALK3with an IC50 of 30
nM, but has no effect on ALK1 in cells (52). LDN193189 also
inhibits ACTR-IIA and ACTR-IIB (53). LDN193189 did not
affect basal responses. However, pre-treatment of HAECs with
LDN193189 decreased the BMP9- or BMP10-induced up-reg-
ulation of E-selectin and VCAM-1 (Fig. 5, A and B). ICAM-1
surface expression levels were only slightly decreased after
LDN193189 treatment (Fig. 5C). Furthermore, LDN193189
reduced monocyte recruitment induced by BMP9 or BMP10
treatment to the level of TNF-only stimulation (Fig. 5,D and E).
The role of BMP type II receptors in the BMP9- and BMP10-
induced expression of adhesionmolecules
As BMPR2 deficiency is associated with pulmonary arterial
hypertension (32, 33) and more recently with atherosclerosis
(35), we investigated the role of the BMP Type II receptors in
mediating the expression of adhesion molecules. Expression
analysis revealed that BMP9 and BMP10 induced the expres-
sion of BMPR2, but not ACVR2A or ACVR2B (supplemental
Fig. S5, A–C). TNF slightly, but nonsignificantly reduced the
expression of BMPR2 (supplemental Fig. S5A). Transfection of
siBMPR2 and siACVR2A, both individually and in combina-
tion, attenuated the BMP9- and BMP10-induced expression of
E-selectin (Fig. 6A) and VCAM-1 (Fig. 6B) in TNF-stimulated
HAECs. In contrast, individual knockdown of BMPR2 and
ACVR2A had no impact on ICAM-1 expression, whereas com-
bined knockdown of these receptors did impair ICAM-1
expression (Fig. 6, A–C). The knockdown efficiency for
siBMPR2 and siACVR2A in HAECs were again85% (supple-
mental Fig. S5, D and E).
Smad1 and Smad5mediate the BMP9- and BMP10-induced
expression of adhesionmolecules on TNF-treated HAECs
To investigate the involvement of Smad1 and Smad5 (26, 54)
inBMP9/BMP10-inducedup-regulation of adhesionmolecules
we employed siRNA knockdown. Unexpectedly, the TNF-in-
duced expression of VCAM-1, ICAM-1, and E-selectin was
inhibited by SMAD1/5 knockdown, in keeping with the possi-
bility that induction of BMP2 by TNF was contributing to
increased expression of these adhesionmolecules (Fig. 7,A–C).
BMP9- and BMP10-induced expression of E-selectin (Fig. 7A)
and VCAM-1 (Fig. 7B) in TNF-stimulated HAECs was mark-
edly impaired upon SMAD1 and SMAD5 knockdown, both
individually and in combination. ICAM-1 expression was only
inhibited when SMAD1 and SMAD5 were knocked-down in
combination (Fig. 7C). SMAD1 and SMAD5 siRNAknockdown
efficiency was confirmed by qPCR and showed an 85% reduc-
tion of the target gene (supplemental Fig. S6, A and B).
Because Smad2 andSmad3have also beendescribed asmedi-
ators of BMP9 signaling (28, 55), we also employed siRNAs
targeting SMAD2 and SMAD3 (supplemental Fig. S6,C andD).
Knockdown of SMAD2 and SMAD3 individually or in combi-
nation did not alter the BMP9- or BMP10-induced surface
expression of adhesionmolecules inHAECs (supplemental Fig.
S7). Collectively, these data show that Smad1/5, but not
Smad2/3, are essential to the BMP9- and BMP10-induced
expression of E-selectin, VCAM-1, and ICAM-1 inTNF-stim-
ulated HAECs.
BMP9 and BMP10 increase IB protein levels, but do not alter
p65/RelA levels or phosphorylation
TNF is known to mediate the expression of cell surface
adhesion receptors via the NF-B pathway (10). We examined
whether BMP9 or BMP10 mediated changes in the levels or
phosphorylation of the canonical signaling proteins, IB and
p65. Both BMP9 and BMP10 increased basal IB protein lev-
els (Fig. 8, A and B), without any impact on IB phosphoryla-
tion or on levels or serine 536 phosphorylation of p65. These
data suggest that BMP9/10 prime endothelial cells for TNF
responsiveness by increasing IB levels.
Discussion
The present study investigated whether BMP9 or BMP10,
important circulating regulators of vascular quiescence, play a
role in monocyte recruitment to the vascular endothelium.
Although BMP9 or BMP10 alone had no effect on monocyte
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recruitment, in the presence of TNF both BMPs synergisti-
cally and in a concentration-dependent manner increased
monocyte recruitment and transmigration. Using siRNA
knockdown of type I receptors and a small molecule inhibitor,
we show that these effects are predominantly mediated by
ALK2 and also involve BMPR-II, ACT-RIIA, and the down-
stream signaling intermediaries, Smad1/5.
The potentiation of TNF-mediated monocyte recruitment
was observed only at higher concentrations of BMP9 or
BMP10, but was also readily induced by BMP6, a ligand with
Figure 4. Effect of ALK1 andALK2 siRNAonBMP9- andBMP10-induced up-regulation of E-selectin, VCAM-1, and ICAM-1 in TNF-stimulatedHAECs.
HAECs were siRNA transfected, then treated with BMP9 or BMP10 (5 ng/ml; 16 h) prior to TNF treatment (0.05 ng/ml for 4 h). Surface expression of E-selectin
(FITC-conjugated anti-human E-selectin) (A), VCAM-1 (PE-Cy5-conjugated anti-human VCAM-1) (B), and ICAM-1 (APC-conjugated anti-human ICAM-1) (C) was
assessed using flow cytometry. Forward scatter and side scatter gatingwas applied to the HAEC population. Data are shown asmedian fluorescence intensity
(MFI) expressed as fold-change relative to HAECs transfected with siRNA control pool (siCP). Experiments were performed in triplicate and the data are
representative of n 3 biological repeats. Error bars represent mean S.E. ***, p 0.001.
BMP9/BMP10 increasesmonocyte recruitment to endothelium
13720 J. Biol. Chem. (2017) 292(33) 13714–13726
high affinity for ALK2. Knockdown of ALK1 and ALK2 in
HAECs demonstrated that the BMP9/10-dependent potentia-
tion of the TNF-stimulated E-selectin expression was entirely
ALK2-dependent, whereas VCAM-1 was partially dependent
on each receptor and ICAM-1 was only altered when both
ALK1 and ALK2 were knocked down. Our data suggest a con-
tribution frombothALK1 andALK2 receptors inmediating the
overall response but a dominance of the ALK2 receptor in the
potentiation of the BMP9- or BMP10-induced monocyte
recruitment to the TNF-stimulated HAECs. BMP9 and
BMP10 both induced the expression of ALK1 and ALK2. The
role of these receptors in atherosclerosis is intriguing, as the
expression of both ALK1 and ALK2 is induced by HDL (56).
Moreover, ALK1 mediates endothelial uptake of LDL, but not
oxidized LDL in LDLR-deficient mice, suggesting a role for
ALK1 in normal endothelial lipid metabolism rather than the
pathogenesis of atherosclerosis (57).
To further investigate the role of type I receptorsweemployeda
small molecule inhibitor of ALK2 and ALK3, LDN193189.
LDN193189 weakly inhibits ALK4, ALK5, ALK7, ACTR-IIA, and
ACTR-IIB (53) at the concentrations used in this study but does
not inhibit ALK1 (52). The results confirm that the monocyte
recruitment and induction of E-selectin, VCAM-1, and ICAM-1
induced by BMP9 or BMP10 in TNF-treated HAECs is largely
independent of ALK1. Our findings also show that BMP9 and
BMP10 synergize with TNF to induce expression of BMP2,
which is a known regulator of endothelial inflammation and plays
a role in atherosclerosis. Increased levels of BMP2 andBMP4have
been observed in atherosclerotic plaques (14–17, 58). Once up-
regulated,BMP2andBMP4 inducean inflammatoryphenotype in
endothelial cells, which results in leukocyte adhesion in vitro.
BMP4 is increased in response to a high fat diet (a risk factor for
atherosclerosis), which then up-regulates BMP2 levels (15). Fur-
thermore, enhancedBMP2activity has been implicated in trigger-
ing and accelerating vascular calcification (14, 15).We and others
have shown previously that TNF increases endothelial expres-
sion ofBMP2 but notBMP4 (12, 59) and thatBMP2 expression in
endothelial cells can be activated by inflammatory stimuli in a
NF-B-dependent manner (59, 60). In our current study neither
TNF, BMP9, nor BMP10 alone impacted on the expression of
BMP2, BMP4, or BMP6 in HAECs. However, HAECs that were
treated with BMP9 or BMP10 in the presence of TNF showed a
synergistic increase in BMP2 expression, providing further evi-
dence that BMP9 and BMP10 are not themselves pro-inflamma-
tory, but instead,might prime the vascular endothelium tomount
a more intense response upon stimulation with an inflammatory
cytokine such as TNF.
Chronic TNF exposure reduces BMPR2 expression in
endothelial cells and can alter BMP signaling (59). Even in this
acute study, low concentrations of TNF reduced basalBMPR2
expression, whereas cell surface E-selectin, ICAM-1, and
VCAM-1 were enhanced. Moreover, both type II receptors,
Figure 5. LDN193189 reduces the BMP9- and BMP10-induced up-regulation of E-selectin, VCAM-1, and ICAM-1 andmonocyte recruitment in TNF-
stimulatedHAECs.HAECswerepre-treatedwith LDN193189 (250nM resuspended inDMSO),DMSO, then stimulatedwithBMP9orBMP10 (5ng/ml; 16h)prior
to TNF treatment (0.05 ng/ml for 4 h). Surface expression of E-selectin (FITC-conjugated anti-human E-selectin) (A), VCAM-1 (PE-Cy5-conjugated anti-human
VCAM-1) (B), and ICAM-1 (APC-conjugated anti-human ICAM-1) (C) was assessed using flow cytometry. Forward scatter and side scatter gating was applied to
the HAEC population. Data are shown as median fluorescence intensity (MFI) expressed as fold-change relative to HAECs transfected with siRNA control pool
(siCP). D, HAECs were treated as described above and then monocytes were perfused in a flow adhesion assay. E, monocyte behavior (rolling, clear bar;
adherence, gray bar; and transmigration, black bar) was expressed as a percentage of total recruitment. Experimentswere performed in triplicate and the data
are representative of n 3 biological repeats. Error bars represent mean S.E. *, p 0.05; **, p 0.01; ***, p 0.001.
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BMPR-II and ACT-RIIA, are essential for BMP9- and BMP10-
induced expression of E-selectin and VCAM-1 in TNF-stim-
ulated HAECs. BMPR-II has been implicated previously in leu-
kocyte-endothelial interactions (38, 39), andBMPR2 deficiency
is associated with several inflammatory vascular pathologies
including pulmonary arterial hypertension (32, 33) and athero-
sclerosis (35). However, there is limited previous information
on the role of ACT-RIIA in the regulation of endothelial-ex-
pressed selectins or adhesions molecules or the process of leu-
kocyte recruitment (28). These findings provide further insight
into the role of endothelial-expressed BMP type II receptors in
maintaining endothelial homeostasis.
We questioned whether the mechanism of the enhanced
TNF response in the presence of BMP9/10 might be due to
their effect on the NF-B pathway, the main pathway known to
induce endothelial adhesion molecules (10). We identified that
BMP9/10 increased IB protein levels, but that the rate of
IB phosphorylation and degradation are not altered. This
implies that the cells are primed for the TNF- response by
BMP9/10. Although we did not observe changes in p65/RelA
levels or Ser-536 phosphorylation, the NF-B family members
are activated by phosphorylation at several serine residues, so
the IB priming may be associated with a different family
member and/or different phosphorylation sites (61).
Figure 6. Knockdown of BMPR2 and ACVR2A inhibits the BMP9- and
BMP10-induced up-regulation of E-selectin, VCAM-1, and ICAM-1 in TNF-
stimulated HAECs. HAECs were siRNA transfected, then treated with BMP9 or
BMP10 (5 ng/ml; 16 h) prior to TNF treatment (0.05 ng/ml; 4 h). Surface expres-
sion of E-selectin (FITC-conjugated anti-human E-selectin) (A), VCAM-1 (PE-Cy5-
conjugated anti-human VCAM-1) (B), and ICAM-1 (APC-conjugated anti-human
ICAM-1) (C) was assessed using flow cytometry. Forward scatter and side scatter
gatingwas applied to the HAEC population. Data are expressed asmedian fluo-
rescence intensity (MFI) expressed as fold-change relative to HAECs transfected
with siRNA control pool (siCP). Experimentswere performed in triplicate and the
data are representative of n 3 biological repeats. Error bars representmean
S.E. *, p 0.05; **, p 0.01; ***, p 0.001.
Figure 7. Smad1andSmad5mediate theBMP9- andBMP10-inducedup-
regulation of E-selectin, VCAM-1, and ICAM-1 in TNF-stimulated
HAECs. HAECs were siRNA transfected, then treated with BMP9 or BMP10 (5
ng/ml, 16 h) prior to TNF treatment (0.05 ng/ml, 4 h). Surface expression of
E-selectin (FITC-conjugated anti-human E-selectin) (A), VCAM-1 (PE-Cy5-con-
jugated anti-human VCAM-1) (B), and ICAM-1 (APC-conjugated anti-human
ICAM-1) (C) was assessedusing flowcytometry. Forward scatter and side scat-
ter gating was applied to the HAEC population. Data are shown as median
fluorescence intensity (MFI) expressedas fold-change relative toHAECs trans-
fected with siRNA control pool (siCP). Experiments were performed in tripli-
cate and the data are representative of n  3 biological repeats. Error bars
represent mean S.E. *, p 0.05; **, p 0.01; ***, p 0.001.
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In the present study, we have shown that BMP9- and
BMP10-induced E-selectin, VCAM-1, and ICAM-1 expression
in TNF-stimulatedHAECs is regulated through the canonical
BMP mediators, Smad1/5 and not Smad2/3. This correlates
with our previous study that reported that Smad1/5 activation
was required for BMP9-induced expression of E-selectin and
VCAM-1 in LPS-stimulated endothelial cells (37). Smad1/5 has
also been reported to mediate the expression of pro-athero-
genic genes that promote atherosclerotic plaque stability in
monocyte-derived macrophages (62). Moreover, inhibition of
BMP signaling using LDN193189 attenuated Smad1/5 activa-
tion and reduced endothelial inflammation and calcification in
atherosclerosis mouse models (63, 64), thus further supporting
our findings that Smad1/5 plays a key role in regulating endo-
thelial homeostasis through the expression of selectins and
adhesion molecules.
Although BMP9 has been more extensively characterized
than BMP10, there is evidence to suggest that BMP9 and
BMP10 can perform overlapping roles. This has been seen in
vitro whereby BMP9 and BMP10 regulate the expression of a
similar set of genes in human microvascular endothelial cells
(24). Furthermore, both BMP9 and BMP10 are required for
complete closure of the ductus arteriosus (65), and BMP10 can
compensate for the absence of BMP9, in BMP9 knock-outmice
during retinal vascularization (21). However, Chen and col-
leagues (66) have shown that BMP9 is not able to substitute for
BMP10 during cardiac development in mice, indicating a dis-
tinct role for BMP10 in cardiogenesis.
Monocyte transmigration across the endothelium is a nor-
mal physiological process but this process can lead to vascular
pathologies and promote atherosclerosis if exaggerated. Here
we show that treatment alone with either BMP9 or BMP10
(even at concentrations 1.5 ng/ml) had no impact on mono-
cyte recruitment in a flow adhesion assay. However, concentra-
tions1.5 ng/ml of BMP9 and BMP10 behave in a near identi-
cal manner to synergize with TNF to up-regulate BMP2
expression and to enhancemonocyte adhesion and transmigra-
tion in HAECs predominantly through ALK2, BMPR-II/ACT-
RIIA, and Smad1/5 signaling. We propose that the beneficial
effects of BMP9 or BMP10 as vascular quiescent factors could
be subverted in the presence of inflammatorymediators such as
TNF (59), contributing to pathological levels of monocyte
recruitment; this in turn might stimulate foam cell develop-
ment, inflammatory cytokine production, and atherosclerotic
plaque development and calcification. Our findings provide
further insight into how BMP signaling mediates endothelial
homeostasis and the mechanisms by which BMPs impact on
cardiovascular disease.
Experimental procedures
Reagents, primers, and antibodies
Cell culture reagents were BMP6, BMP9, and BMP10 (R&D
Systems) and LDN193189 used at a working concentration of
250 nM (stock resuspended in DMSO at 5 mM, a kind gift from
Professor Paul Yu, Department of Medicine, Harvard Univer-
sity) EGM-2 BulletKit (Lonza), fetal bovine serum (FBS)
(Sigma), trypsin (Sigma), Histopaque 1077 and 1119 (Sigma),
Dulbecco’s phosphate-buffered saline (PBS) with Ca2,Mg2
(Sigma), albumin bovine fraction (BSA) V solution 7.5%
(Sigma), magnetic-activated cell sorting (MACS) separation
system (Miltenyi Biotec), LS columns (Miltenyi Biotec), and
CD14 microbeads (Miltenyi Biotec). siRNA transfection re-
agents were DharmaFECT1TM (Dharmacon), ON-TARGET-
plusTM siRNA Pools (Dharmacon), namely siALK1, siALK2,
siSMAD1, siSMAD2, siSMAD3, siSMAD5, siBMPR2, siACVR2A,
siACVR2B, and non-targeting siRNA Pool (siCP). Flow cytom-
etry reagents were anti-hE-selectin fluorescein-conjugated
mouse IgG1(anti-human E-selectin-FITC, R&D Systems), allo-
phycocyanin (APC) mouse anti-human CD54 (anti-human
ICAM-1-APC, BD Pharmingen), and PE/Cy5 anti-human
CD106 (anti-human VCAM-1-PECy5, BioLegend). Flow
cytometry isotype control antibodies: mouse IgG1 isotype
control fluorescein (R&D Systems), APC-mouse IgG1 (BD
Pharmingen), andPE/Cy5mouse IgG1 isotype control (BioLeg-
end). Western blotting antibodies were IB mouse mAb,
phospho-Ser32/36-IB rabbit Ab, p65/RelA rabbit mAb, or
phospho-Ser536-p65 rabbit Ab (Cell Signaling Technologies).
qPCR reagents were QuantiTect Primer Assays (Qiagen)
namely Hs-ACVRL1_1_SG (ALK1), Hs_ACVR1_1_SG (ALK2),
SMAD2, SMAD3, and ACVR2A. Primer sequences were
BMPR2 forward, 5-CAAATCTGTGAGCCCAACAGTCAA-
3; BMPR2 reverse, 5-GAGGAAGAATAATCTGGATAAG-
GACCAAT-3; SMAD1 forward, 5-TAGAAAGCCCTGTAC-
Figure8.BMP9andBMP10 increase IB-protein levels inHAECs.HAECs
were treated with BMP9 or BMP10 (5 ng/ml, 16 h) prior to TNF treatment
(0.05 ng/ml) for 15 or 30 min. A, protein lysates were immunoblotted for
IB-, phospho-Ser32/36-IB (P-IB-), p65/RelA (p65), or phospho-Ser536-
p65 (P-p65). All blots were reprobed for -tubulin to confirm equal loading.
Blots are representative of n 3 separate experiments. B, densitometry was
determinedusing ImageJ for the three IBblots, eachbandbeingexpressed
as a ratio of IB/-tubulin. These ratios were then normalized to the 0.1%
control for the relevant time point.
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TTCCTC-3; SMAD1 reverse, 5-GGTTGCTGGAAAGAAT-
CTGG-3; SMAD5 forward, 5-GAGAGTCCAGTCTTACC-
TCC-3; SMAD5 reverse, 5-GGAAAGAATCTGGAAACGT-
G-3; PBGD forward, 5-AGCTATGAAGGATGGGCAAC-3;
PBGD reverse, 5-TTGTATGCTATCTGAGCCGTCTA-3;
B2M forward, 5-CTCGCGCTACTCTCTCTTTC-3; B2M
reverse, 5-CATTCTCTGCTGGATGACGTG-3; HPRT for-
ward, 5-GCTATAAATTCTTTGCTGACCTGCTG-3; HPRT
reverse, 5-AATTACTTTATGTCCCCTGTTGACTGG-3. ROX
referencedye (Invitrogen) andSYBRGreen JumpStartTaqReady-
Mix (Sigma) were used.
Endothelial cell culture
HAECs were purchased from PromoCell and maintained in
EGM2-mv (Lonza) with 5% FBS. HAECs were cultured at 37 °C
in a 5%CO2 humidified atmosphere and used in experiments at
passages 4–6.HAECswere treatedwith BMP6, BMP9, BMP10,
or with LDN193189 with the indicated concentrations for 16 h
prior stimulation with TNF (0.05 ng/ml; 4 h).
BOECs were generated from peripheral blood of control vol-
unteers as described previously (46). Full informedwritten con-
sent was obtained under ethical approval from the Huntington
Local Research Ethics Committee.
Monocyte isolation
Blood samples were derived from healthy volunteers after
giving informed consent, according to the protocol approved by
the Cambridge Research Ethics Committee (06/Q018/218).
Two-step density gradients of Histopaque 1119 and 1077
(Sigma) were used to isolate peripheral blood mononuclear
cells. CD14 monocytes were isolated from peripheral blood
mononuclear cells through positive selection using magnetic-
activated cell sorting as per the manufacturer’s instructions.
CD14monocyteswere resuspended at a cell density of 1 106
cells/ml in 0.15% BSA in PBS (with Ca2 and Mg2).
siRNA transfection
HAECs were transfected with siRNA at 10 nM final concen-
tration, using DharmaFECT1TM transfection reagent, follow-
ing the manufacturer’s instructions, 48 h prior to their use in
cell culture experiments.
Monocyte-endothelial interactions under flow
An in vitro flow adhesion assay was used to assess
endothelial–monocyte interactions as previously described
(67). Themicroslide (-SlideVI0.4; Ibidi), containing theHAEC
monolayer was connected to cell and wash reservoirs by silicon
tubing and a valve enabled switching between the two reser-
voirs with continuous flow. The flow rate of 1  106 mono-
cytes/ml for 4 min, equivalent to a wall shear stress of 0.1 Pas-
cals, was controlled using a glass syringe attached to a
withdrawal pump. Monocyte–endothelial interactions were
visualized using time lapse imaging at 6 min post the initial
monocyte bolus using a phase-contrast microscope, placed
within a Perspex environmental chamber at 37 °C. Quantifica-
tion of monocyte behavior including rolling, arrest, and trans-
migration was performed offline using ImagePro software.
Flow cytometric analysis of surface proteins
Flow cytometric analysis of endothelial cell surface adhesion
proteins was performed as previously described (34) using anti-
humanE-selectin-FITC, anti-humanVCAM-1-PE-Cy5, and anti-
human ICAM-APC with corresponding conjugated isotype con-
trols. Analysis was performed using a BD FACSCantoTM II (BD
Biosciences) and quantification was performed using FlowJo
software.
qPCR
An RNAeasy Mini kit (Qiagen) was used to extract the
total RNA extracted from HAECs. mRNA expression of the
genes of interest was assessed using SYBR Green Jumpstart
Taq ReadyMix, ROX reference dye, and primers (Quantitect
Primer Assays or in-house designed primers) in a 384-well
QuantStudio 6 Flex (Applied Biosystems, Life Technolo-
gies). The Ct method was used for quantification.
Western blotting
HAECswere seeded in 6-cmdishes and grown to confluence.
Cells were then incubated in EBM2 (Lonza) with 0.1% FBS
(0.1% FBS) for 2 h and then treatedwith BMP9, BMP10, or 0.1%
FBS for 16 h. Cells were then treatedwith TNF (0.05 ng/ml) or
0.1% FBS for 15 or 30 min. Cells were snap-frozen and lysed in
250 mM Tris-HCl, pH 6.8, 4% SDS, 20% (v/v) glycerol contain-
ing an EDTA-free protease inhibitor mixture (Roche Applied
Science, West Sussex, UK). Lysates were immunoblotted for
the relevant proteins.
Statistical analysis
Comparisons between two groups were made using an
unpaired Student’s t test. Comparisons between three or more
groups were performed using one-way analysis of variance with
Tukey’s multiple comparisons. A probability (p value) smaller
than 0.05 was considered statistically significant. Normality of
data distribution was assessed using a D’Agostino and Pearson
omnibus normality test. Data are presented as the mean S.E.
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